8-K current report · filed Aug 21, 2026

Oncology Institute, Inc. (TOI) 8-K Current Report: August 21, 2026

Item 1.01Item 2.03TOI overview

Short answer

Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on August 21, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). $25 million revolving credit facility, providing working-capital flexibility through August 20, 2029.

Oncology Institute, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $25 million revolving credit facility, providing working-capital flexibility through August 20, 2029
  • $4.75 million outstanding at closing, secured by substantially all SOM, LLC collateral
  • Borrowing-base availability tied to accounts receivable, with lockbox controls over specified professional corporations
  • Interest at Term SOFR plus 3.95%, with Term SOFR floor of 2.00% and 5.00% default-rate premium
  • Minimum-use and termination fees increase financing costs, while covenants restrict additional debt, distributions, investments and liens

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 incorporates Item 1.01, indicating a newly created direct financial obligation or off-balance-sheet arrangement
  • Obligation terms, amount, maturity, interest rate and intended use require review of Item 1.01 or its exhibit

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Oncology Institute, Inc. 8-K filings

Get the next TOI 8-K as it lands

Follow TOI for push alerts, or ask the research agent what this filing means.